Population Stratification Sample Clauses

Population Stratification. Re-id for direct care purposes only
Sample 1Sample 2Sample 3See All (4)
AutoNDA by SimpleDocs
Population Stratification. Re-id in controlled environment for direct care purposes only
Sample 1Sample 2Sample 3See All (4)
Population Stratification. Re-id in controlled environment for direct care purposes only 5 Medications Use Case 3: Population Stratification Use Case 4: Place Based COVID related analysis as outlined in the COPI Notice
Sample 1Sample 2Sample 3See All (4)
Population Stratification. Use Case 4: Place Based COVID related analysis as outlined in the COPI Notice
Sample 1Sample 2Sample 3See All (4)
Population Stratification. Use Case 4: Place Based COVID related analysis as outlined in the COPI Notice 10 Additional GP Information • GP Encounter • Vaccinations & Immunisations • Contraindications • OTC and Prophylactic Therapy • Family History Use Case 1: Demand and Capacity Use Case 3: Population Stratification. • Child Health • Diabetes Diagnosis • Chronic Disease Monitoring • Medication Administration • Pregnancy, Birth and Post Natal • Contraception and HRT • GP Imaging • Other Investigations • Investigations Administration • Operations • Obstetric Procedures • Other Diagnostic Procedures • ECG • Other Preventative Procedures • Other Therapeutic Procedures • Recent Test Results (last 12 months) Use Case 4: Place Based COVID related analysis as outlined in the COPI Notice 12 Data Categories • Active Problems • Administration • Alcohol Exercise and Diet • Allergy • Blood Chemistry • Blood Pressure • Cervical Cytology • Child Health • Chronic Disease Monitoring • Contraception and HRT • Contraindications • Diabetes Diagnosis • ECG Pulmonary • Encounters • Family History • Full Problems List • Glucose/hba1c • Haematology • Height and Weight • Imaging • Investigations Admin • Medications Administration • Medication Issues • Microbiology • Obstetric Procedures • Operations • OTC Prophylactic Therapy • Other Cytology/Pathology • Other Diagnostic Procedures • Other Investigations • Other Preventative Procedures • Other Therapeutic Procedures • Past Problems • Physiology Function Tests • Pregnancy, Birth and Post Natal • Recent Tests Use Case 1: Demand and Capacity Use Case 2: Epidemiology Use Case 3: Population Stratification. Use Case 4: Place Based COVID related analysis as outlined in the COPI Notice • Referrals and Admissions • Repeat Medication • Smoking • Social History • Unmatched • Urinalysis • Vaccination and Immunisations
Sample 1Sample 2See All (4)
Population Stratification. Use Case 4: Place Based COVID related analysis as outlined in the COPI Notice ANNEX C – Sensitive Codes Rubric Filter HSA1-Therap. Abort. Green Form 956% H/O: Venereal Disease 1415% Hysterotomy And Termination Of Pregnancy 7E066% Dilation Of Cervix Uteri And Curettage Of Products Of Conception From Uterus 7E070% Curettage Of Products Of Conception From Uterus NEC 7E071% Suction Termination Of Pregnancy 7E084% Dilation Of Cervix And Extraction Termination Of Pregnancy 7E085% Termination Of Pregnancy NEC 7E086% Cervical Smear 4K36% Cervical Smear 4K36% Gonorrhoea 65Q8% Introduction Of Abortifacient Into Uterine Xxxxx 0X0X% Introduction Of Abortifacient Into Uterine Tract 7E0B% Genital Herpes A541% Viral Hepatitis B With Coma A702% Viral Hepatitis B With Serum A703% Other Spec Viral Hepatitis With Coma A7040% Viral Hepatitis C Without Mention Of Hepatitis Coma A7050% Chronic Viral Hepatitis A707% Unspecified Viral Hepatitis A70z% Cytomegalic Hepatitis A7852% HIV Resulting In Cytomegalic Disease A7891% Chlamydia A78A0% Chlamydia Anus And Rectum A78A2% Human Papilloma Virus Infection A79B% Papilloma As Cause Of Diseases Class. In Other Chapters A7y05% Trichomonas AD1% Phthrius Pubis Lice AD22% Sexual Deviations E22y4% Gender Identity Disorders Eu64% Cystitis In Gonorrhea K1545% Prostatitis In Gonorrhea K2144% Prostatitis In Trichomonosis K2146% Chlamydia Epidymitis K2416% Female Chlamydia In Pelvic Infumonotary K40y1% Chlamydia Cervilitis K4209% Unspecified Abortion L07% Failed Attempted Abortion L08% Complication Following Abortion/Ectopic/ Molar Pregnancies L09% Failed Attempted Abortion L0A% Failed Attempted Abortion L0A% Other Specified Pregnancy With Abortive Outcome L0y% Pregnancy With Abortive Outcome NOS L0z% Maternal Syphilis In Pregnancy/Childbirth/Peurperium L170% Maternal Gonorrhea In Pregnancy/Childbirth/Peurperium L171% Lab Evidence Of HIV R109% Complications Assoc With Artificial Fertilization SPOD% Gonorrhea Carrier ZV027% Hepatitis B Carrier ZV02B% Hepatitis C Carrier ZV02C% High Risk Pregnancy With History Of Infertility ZV230% Contraception Mgt Admission Of Administration Of Abortifacient ZV25B% IVF ZV267% Venereal Disease Carrier NOS 65Q9% AIDS Carrier 65QA% Notification Of AIDS 65VE% Treatment For Infertility 8C8% Acquired Immune Deficiency Syndrome A788% Human Immunodef Virus Resulting In Other Disease A789% Chlamydial Infection A78A% Chlamydial Infection Of Pelviperitoneum And Other Genitourinary Organs A78A3% Chlamydial Infection, Unspec...
Sample 1Sample 2
Population Stratification. Use Case 4: Place Based COVID related analysis as outlined in the COPI Notice 4 Allergies Summary
Sample 1
AutoNDA by SimpleDocs
Population Stratification. Use Case 4: Place Based COVID related analysis as outlined in the COPI Notice 6 GP Problems • Active Problems • Past Problems • Additional Problems Use Case 2: Epidemiology Use Case 3: Population Stratification. Use Case 4: Place Based COVID related analysis as outlined in the COPI Notice
Sample 1
Population Stratification. The population shall be stratified and reported by race and ethnicity in accordance with the associated measure specifications.
Sample 1

Related to Population Stratification

  • Study Population ‌ Infants who underwent creation of an enterostomy receiving postoperative care and awaiting enterostomy closure: to be assessed for eligibility: n = 201 to be assigned to the study: n = 106 to be analysed: n = 106 Duration of intervention per patient of the intervention group: 6 weeks between enterostomy creation and enterostomy closure Follow-up per patient: 3 months, 6 months and 12 months post enterostomy closure, following enterostomy closure (12-month follow-up only applicable for patients that are recruited early enough to complete this follow-up within the 48 month of overall study duration).

  • Target Population The Grantee shall ensure that diversion programs and services provided under this grant are designed to serve juvenile offenders who are at risk of commitment to Department.

  • Population The Population shall be defined as all Paid Claims during the 12-month period covered by the Claims Review.

  • Staffing Plan 8.l The Board and the Association agree that optimum class size is an important aspect of the effective educational program. The Polk County School Staffing Plan shall be constructed each year according to the procedures set forth in Board Policy and, upon adoption, shall become Board Policy.

  • How to File an Appeal of a Prescription Drug Denial For denials of a prescription drug claim based on our determination that the service was not medically necessary or appropriate, or that the service was experimental or investigational, you may request an appeal without first submitting a request for reconsideration. You or your physician may file a written or verbal prescription drug appeal with our pharmacy benefits manager (PBM). The prescription drug appeal must be submitted to us within one hundred and eighty (180) calendar days of the initial determination letter. You will receive written notification of our determination within thirty (30) calendar days from the receipt of your appeal. How to File an Expedited Appeal Your appeal may require immediate action if a delay in treatment could seriously jeopardize your health or your ability to regain maximum function, or would cause you severe pain. To request an expedited appeal of a denial related to services that have not yet been rendered (a preauthorization review) or for on-going services (a concurrent review), you or your healthcare provider should call: • our Grievance and Appeals Unit; or • our pharmacy benefits manager for a prescription drug appeal. Please see Section 9 for contact information. You will be notified of our decision no later than seventy-two (72) hours after our receipt of the request. You may not request an expedited review of covered healthcare services already received.

  • Monitoring Plan keep up with the objectives from the cadetship practice booklet; taking daily notes as well as learning new information every day; currently reporting to the supervisor. Evaluation plan: the final result should be in accordance with the traineeship’s aims and objectives, achieving an improvement of specialty knowledge and language skills. The level of language competence9 in English that the trainee already has or agrees to acquire by the start of the mobility period is: A1 ☐ A2 ☐ B1 ☐ B2 ☒ C1 ☐ C2 ☐ Native speaker ☐ Table B - Sending Institution Please use only one of the following three boxes: 10 The traineeship is embedded in the curriculum and upon satisfactory completion of the traineeship, the institution undertakes to:Award ……...…ECTS credits (or equivalent)11 Give a grade based on: Traineeship certificate ☒ Final report ☒ Interview ☐ Record the traineeship in the trainee's Transcript of Records and Diploma Supplement (or equivalent). Record the traineeship in the trainee's Europass Mobility Document: Yes ☒ No ☐ The traineeship is voluntary and, upon satisfactory completion of the traineeship, the institution undertakes to: Award ECTS credits (or equivalent): Yes ☐ No ☐ If yes, please indicate the number of credits: …. Give a grade: Yes ☐ No ☐ If yes, please indicate if this will be based on: Traineeship certificate ☐ Final report ☐ Interview ☐ Record the traineeship in the trainee's Transcript of Records: Yes ☐ No ☐ Record the traineeship in the trainee's Diploma Supplement (or equivalent). Record the traineeship in the trainee's Europass Mobility Document: Yes ☐ No ☐ The traineeship is carried out by a recent graduate and, upon satisfactory completion of the traineeship, the institution undertakes to: Award ECTS credits (or equivalent): Yes ☐ No ☐ If yes, please indicate the number of credits: …. Record the traineeship in the trainee's Europass Mobility Document (highly recommended): Yes ☐ No ☐ Accident insurance for the trainee The Sending Institution will provide an accident insurance to the trainee (if not provided by the Receiving Organisation/Enterprise): Yes ☐ No ☒ The accident insurance covers: - accidents during travels made for work purposes: Yes ☐ No ☒ - accidents on the way to work and back from work: Yes ☐ No ☒

  • Designated Prescription Drug Prescribers and Pharmacies We may limit your selection of a pharmacy to a single pharmacy location and/or a single prescribing provider or practice. Those members subject to this designation include, but are not limited to, members that have a history of: • being prescribed prescription drugs by multiple providers; • having prescriptions drugs filled at multiple pharmacies; • being prescribed certain long acting opioids and other controlled substances, either in combination or separately, that suggests a need for monitoring due to: o quantities dispensed; o daily dosage range; or o the duration of therapy exceeds reasonable and established thresholds. The Amount You Pay for Prescription Drugs Our formulary includes a tiered copayment structure, which means the amount you pay for a prescription drug will vary by tier. See the Summary of Pharmacy Benefits for your copayment structure, benefit limits and the amount you pay. When you buy covered prescription drugs and diabetic equipment and supplies from a retail network pharmacy, you will be responsible for the copayment and deductible (if any) at the time of purchase. You will be responsible for paying the lower of your copayment, the retail cost of the drug, or the pharmacy allowance. Specialty prescription drugs are generally obtained from a specialty pharmacy. If you buy a specialty prescription drug from a retail network pharmacy, you will be responsible for a significantly higher out of pocket expense than if you bought the specialty drug from a specialty pharmacy. The amount you pay for the following prescription drugs is not subject to the tiered copayment structure: • Contraceptive methods; • Over-the-counter (OTC) preventive drugs; • Nicotine replacement therapy (NRT) and smoking cessation prescription drugs; • Infertility specialty prescription drugs; and • Covered diabetic equipment or supplies bought at a network pharmacy. See the Summary of Pharmacy Benefits for benefit limits and the amount you pay. This plan allows for medication synchronization in accordance with R.I. General Law

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Prescription Drug Plan Effective July 1, 2011, retail and mail order prescription drug copays for bargaining unit employees shall be as follows: Type of Drug Prescriptions for 1-45 Days (1 copay) Prescriptions for 46-90 Days (2 copays) Generic drug $10 $20 Preferred brand name drug $25 $50 Non-preferred brand name drug $40 $80 Effective July 1, 2011, for each plan year the Prescription Drug annual out-of- pocket copay maximum shall be $1,000 for individual coverage and $1,500 for employee and spouse, employee and child, or employee and family coverage.

  • Financial Viability and Regulatory Compliance 4.6.1 The Contractor warrants and represents that its corporate entity is in good standing with all applicable federal, state, and local licensing authorities and that it possesses all requisite licenses to perform the services required by this contract. The Contractor further warrants and represents that it owes no outstanding delinquent federal, state, or local taxes or business assessments.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!